-
Product Insights
NewNet Present Value Model: Sandoz Group AG’s Ustekinumab Biosimilar
Empower your strategies with our Net Present Value Model: Sandoz Group AG's Ustekinumab Biosimilar report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Sandoz Group AG’s Aflibercept Biosimilar
Empower your strategies with our Net Present Value Model: Sandoz Group AG's Aflibercept Biosimilar report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Denosumab Biosimilar in Bone Metastasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Denosumab Biosimilar in Bone Metastasis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Denosumab Biosimilar in Bone Metastasis Drug Details: Denosumab (Jubbonti), is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Denosumab Biosimilar in Post Menopausal Osteoporosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Denosumab Biosimilar in Post Menopausal Osteoporosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Denosumab Biosimilar in Post Menopausal Osteoporosis Drug Details: denosumab biosimilar...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Denosumab Biosimilar in Humoral Hypercalcemia of Malignancy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Denosumab Biosimilar in Humoral Hypercalcemia of Malignancy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Denosumab Biosimilar in Humoral Hypercalcemia of Malignancy Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Denosumab Biosimilar in Giant Cell Tumor Of Bone
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Denosumab Biosimilar in Giant Cell Tumor Of Bone report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Denosumab Biosimilar in Giant Cell Tumor Of...
-
Product Insights
NewArthralgia (Joint Pain) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Arthralgia Clinical Trial Report Overview A total of 713 Arthralgia clinical trials were conducted as of March 2024. The Arthralgia clinical trial report provides a comprehensive understanding of the Arthralgia clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·       North America ·       Europe ·       Asia-Pacific ·       ...
-
Product Insights
NewObsessive-Compulsive Disorder Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Obsessive-Compulsive Disorder Clinical Trial Market Report Overview Obsessive-compulsive disorder clinical trial market research report provides top line data relating to the clinical trials on obsessive-compulsive disorder. The report includes an overview of trials count and their average enrollment in top countries conducted globally. The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status and sponsor type. The report also provides prominent drug names and trial counts for in-progress trials. Key...
-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Thematic Analysis
Biosimilars in Oncology – Thematic Intelligence
Accessing in-depth insights from the ‘Biosimilars in Oncology’ report will help you: Understand the milestones of biosimilars in oncology, the trends in the market, and the biosimilar value chain. Assess the marketed and pipeline products and their uptake across 8MM. Learn about the percentage of cancer patients treated with biosimilars, the price of the agents compared to their originator, and key opinion leaders’ outlook for the products. Examine the 8MM regulatory landscapes, their market potential, and their available and upcoming biosimilars....